Edition:
United States

Bill Berkrot

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

Apr 27 2017

Biomarin sets high price for rare pediatric brain disease drug

Biomarin Pharmaceuticals Inc said the annual price for its drug, which won U.S. approval on Thursday, to treat a rare and fatal type of pediatric brain disease is expected to be $486,000 after mandatory government discounts and rebates.

Apr 27 2017

Celgene 1st quarter sales miss; expects psoriasis drug rebound

Celgene Corp on Thursday reported lower-than-expected first-quarter revenue with Otezla sales well short of Wall Street estimates, but the U.S. biotechnology company promised the psoriasis drug was poised to rebound.

Apr 26 2017

Cost controls help offset lower Amgen first-quarter drug sales

Amgen Inc on Wednesday reported higher-than-expected first-quarter profit as cost controls helped offset a sharp drop in sales of Enbrel, its blockbuster rheumatoid arthritis and psoriasis drug.

Apr 25 2017

Lilly gives no time frame on arthritis drug delay; shares fall

Eli Lilly and Co on Tuesday provided no new information on how long U.S. regulators might delay approval of its closely watched rheumatoid arthritis drug after its surprise rejection by the Food and Drug Administration this month.

Apr 24 2017

NASH - The next untapped pharma market gives investors many options

Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020. | Video

Apr 24 2017

NASH: The next untapped pharma market gives investors many options

Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020. | Video

Apr 24 2017

INSIGHT-NASH: The next untapped pharma market gives investors many options

April 24 Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020.

Apr 22 2017

Bristol-Myers NASH drug reduces liver fat in midstage study

Bristol-Myers Squibb Co said its lead experimental drug for nonalcoholic steatohepatitis, or NASH, significantly reduced liver fat versus placebo, according to data from a mid-stage trial presented at a medical meeting on Saturday.

Apr 18 2017

Intuitive Surgical raises 2017 procedure growth forecast

Intuitive Surgical Inc on Tuesday increased its 2017 forecast for growth in procedures using its da Vinci surgical robots after reporting higher-than-expected first-quarter revenue and profit, and its shares rose nearly 4 percent.

Apr 18 2017

J&J first quarter revenue misses estimates; new forecast includes Actelion

Johnson & Johnson on Tuesday reported disappointing pharmaceutical and consumer product sales as revenue missed analyst estimates, sending its shares sharply lower.

More From Around the Web

Markets

  • U.S.
  • Europe
  • Asia
  • Sectors

Sector Summary